[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 7 of about 7
1. Murthy R, Honavar SG, Burman S, Vemuganti GK, Naik MN, Reddy VA: Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis. Ophthal Plast Reconstr Surg; 2005 Jul;21(4):307-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis.
  • A 55-year-old Asian Indian woman who had recurrent sebaceous gland carcinoma of the left lower eyelid with orbital extension and regional lymph node metastasis was treated with neoadjuvant chemotherapy, using a combination of carboplatin and 5-fluorouracil.
  • Eyelid-sparing orbital exenteration was performed after 3 cycles of chemotherapy, followed by radiotherapy to the regional lymph nodes.
  • Subsequently, 3 cycles of adjuvant chemotherapy were administered.
  • Significant eyelid and orbital tumor volume reduction was achieved with neoadjuvant chemotherapy, making eyelid-sparing orbital exenteration possible.
  • Chemotherapy also spared the patient from radical neck dissection.
  • The patient had limited morbidity and was free of local, regional, and systemic disease at 26 months of follow-up.
  • [MeSH-major] Adenocarcinoma, Sebaceous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Eyelid Neoplasms / drug therapy. Orbital Neoplasms / drug therapy. Sebaceous Gland Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16052148.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Shields CL, Naseripour M, Shields JA, Eagle RC Jr: Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma. Ophthalmology; 2002 Nov;109(11):2129-33
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma.
  • PURPOSE: To evaluate the efficacy of topical mitomycin-C for pagetoid invasion of the conjunctiva by sebaceous gland carcinoma.
  • INTERVENTION: All patients received topical 0.04% mitomycin-C four times daily for 1 week followed by 1 week off medication.
  • The treatment cycles were repeated until resolution of the conjunctival malignancy was clinically evident.
  • PARTICIPANTS: Four patients with histopathologically proven intraepithelial (pagetoid) invasion of the conjunctiva by sebaceous gland carcinoma were managed with this regimen.
  • Before treatment, the main tumor site included the upper eyelid in two cases and the lower eyelid in two cases.
  • Previous resection of the tumor had been performed elsewhere in three cases over the prior 6 years.
  • At the time of our examination, map biopsies confirmed pagetoid invasion involving 25% to 90% of the conjunctival surface, with bulbar, forniceal, and tarsal conjunctival involvement in all four cases and corneal extension in one case.
  • There was no evidence of deep tumor within the conjunctival stroma or tarsus in any case.
  • After treatment, medication intolerance and early discontinuation occurred in one patient, and continued tumor progression was documented.
  • Of the remaining three patients, chemotherapy was used for a mean of four cycles with complete resolution of the pagetoid invasion, confirmed histopathologically in two cases, and without recurrence in all three cases over 12 months (mean) follow-up.
  • The medication caused moderate temporary local irritation but no serious intraocular or extraocular complications.
  • CONCLUSIONS: Preliminary evidence suggests that topical mitomycin-C is effective treatment for pagetoid invasion of the conjunctiva by sebaceous gland carcinoma.
  • Longer follow-up is necessary to assess the duration of tumor control.
  • [MeSH-major] Adenocarcinoma, Sebaceous / drug therapy. Antibiotics, Antineoplastic / therapeutic use. Conjunctival Neoplasms / drug therapy. Eyelid Neoplasms / drug therapy. Mitomycin / therapeutic use. Sebaceous Gland Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Female. Humans. Male. Neoplasm Invasiveness. Prospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12414427.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


3. Husain A, Blumenschein G, Esmaeli B: Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol; 2008 Mar;47(3):276-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid.
  • OBJECTIVE: To report the management and outcomes in patients with metastatic eyelid sebaceous cell carcinoma.
  • METHODS: The clinical records of four patients with metastatic eyelid sebaceous cell carcinoma treated between January 1999 and August 2006 were reviewed.
  • Time from diagnosis of eyelid carcinoma to metastasis ranged from 0 to 62 months.
  • Treatment of regional nodal metastasis consisted of complete neck dissection followed by radiation therapy.
  • One patient developed lung metastasis 5 years after the diagnosis of eyelid tumor; she was treated with systemic chemotherapy followed by subtotal lung resection.
  • Systemic chemotherapy was considered for two additional patients: in one, chemotherapy was deferred due to poor performance status and ongoing medical problems; and another patient died before chemotherapy could be started.
  • The patient with bony metastasis was treated with radiation therapy to the spine.
  • The follow-up time from diagnosis of metastasis to last contact or death ranged from 1 month to 3 years (median of 21 months).
  • CONCLUSION: Eyelid sebaceous cell carcinoma can result in systemic metastasis and death.
  • Metastasis can be discovered as late as 5 years after treatment of the eyelid carcinoma, warranting continued surveillance.
  • Treatment of metastatic disease may include a combination of chemotherapy, radiation, and surgical neck dissection.
  • [MeSH-major] Adenocarcinoma, Sebaceous / secondary. Bone Neoplasms / secondary. Eyelid Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Parotid Neoplasms / secondary. Sebaceous Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Chalazion / diagnosis. Diagnostic Errors. Female. Humans. Lymphatic Metastasis / radiotherapy. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289332.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Shields JA, Demirci H, Marr BP, Eagle RC Jr, Stefanyszyn M, Shields CL: Conjunctival epithelial involvement by eyelid sebaceous carcinoma. The 2003 J. Howard Stokes lecture. Ophthal Plast Reconstr Surg; 2005 Mar;21(2):92-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjunctival epithelial involvement by eyelid sebaceous carcinoma. The 2003 J. Howard Stokes lecture.
  • PURPOSE: To determine incidence and distribution of conjunctival epithelial involvement by eyelid sebaceous carcinoma and to make recommendations regarding its management.
  • METHODS: The medical records were reviewed retrospectively on patients with histopathologically confirmed sebaceous carcinoma of the eyelids managed at the Oncology Service at Wills Eye Hospital.
  • The incidence of metastasis and tumor-related mortality was determined.
  • Based on these findings and personal surgical experience, recommendations are made regarding management of eyelid sebaceous carcinoma with involvement of the conjunctival epithelium.
  • RESULTS: Of 60 patients with sebaceous carcinoma, epithelial involvement of the conjunctiva was identified in 28 (47%).
  • Of the 28 cases, the neoplasm affected the following sites: superior tarsal and fornical conjunctiva in 28 (100%), inferior tarsal conjunctiva in 19 (68%), inferior fornical conjunctiva in 18 (64%), superior bulbar conjunctiva in 19 (68%), and inferior bulbar conjunctiva in 16 (57%).
  • Map biopsies, combined with cryotherapy, topical chemotherapy, local surgical resection, and orbital exenteration, were used to achieve local control.
  • CONCLUSIONS: Eyelid sebaceous carcinoma was found to exhibit epithelial involvement of the conjunctiva in 47% of cases, predominantly in the superior tarsal and fornical conjunctiva and less often in the inferior tarsal conjunctiva, caruncle, and cornea.
  • Treatment of this condition is challenging, and map biopsy, cryotherapy, topical chemotherapy, and newer surgical methods are being used more often by our group.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Carcinoma in Situ / pathology. Conjunctival Neoplasms / pathology. Eyelid Neoplasms / pathology. Sebaceous Gland Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cryotherapy. Humans. Incidence. Ophthalmologic Surgical Procedures. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15778660.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Lectures; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Babilas P, Szeimies RM: The use of photodynamic therapy in dermatology. G Ital Dermatol Venereol; 2010 Oct;145(5):613-30
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of photodynamic therapy in dermatology.
  • In dermatology, topical photodynamic therapy (PDT) is a well established treatment modality which has mainly shown to be effective for dermato-oncologic conditions like actinic keratosis, Bowen's disease, in-situ squamous cell carcinoma and superficial basal cell carcinoma.
  • However, a therapeutical benefit of PDT is also evident for inflammatory dermatoses like localized scleroderma, acne vulgaris and granuloma annulare as well as for aesthetic indications like photo aged skin or sebaceous gland hyperplasia.
  • These drugs do not induce strong generalized cutaneous photosensitization like the systemically applied porphyrins or their derivatives.
  • Depending on the applied light dose and the concentration of the photosensitizer either cytotoxic effects resulting in tumor destruction or immunomodulatory effects improving the inflammatory conditions occur.
  • Treating superficial oncologic lesions (tumor thickness < 2-3 mm) cure rates achieved by PDT are equal to the cure rates of the respective standard therapeutic procedure.
  • The benefits of PDT are the low level of invasiveness and the excellent cosmetic results after treatment.
  • [MeSH-major] Photochemotherapy. Skin Diseases / drug therapy
  • [MeSH-minor] Acne Vulgaris / drug therapy. Carcinoma, Basal Cell / drug therapy. Cosmetic Techniques. Humans. Keratosis, Actinic / drug therapy. Light. Photosensitizing Agents / therapeutic use. Psoriasis / drug therapy. Skin Neoplasms / drug therapy. Warts / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20930696.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa╠Ç italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  •  go-up   go-down


7. Poothullil AM, Colby KA: Topical medical therapies for ocular surface tumors. Semin Ophthalmol; 2006 Jul-Sep;21(3):161-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical medical therapies for ocular surface tumors.
  • We review the use of three topical medications for the therapy of ocular surface tumors: mitomycin C, 5-fluorouracil, and interferon alpha-2B.
  • Topical agents were used as both primary and adjuvant therapy.
  • Rates of tumor regression for CIN and squamous cell carcinoma ranged from 80 to 96%, and 70% of pigmented tumors regressed after an average follow-up of 27 months.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Interferon-alpha / administration & dosage. Interferon-alpha / adverse effects. Lymphoma / drug therapy. Lymphoma / pathology. Mitomycin / administration & dosage. Mitomycin / adverse effects. Recombinant Proteins. Sebaceous Gland Neoplasms / drug therapy. Sebaceous Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912014.001).
  • [ISSN] 0882-0538
  • [Journal-full-title] Seminars in ophthalmology
  • [ISO-abbreviation] Semin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 50SG953SK6 / Mitomycin; 99210-65-8 / interferon alfa-2b; U3P01618RT / Fluorouracil
  • [Number-of-references] 52
  •  go-up   go-down






Advertisement